Insulatard Innolet (Insulin Human)

Insulin Human mimics the action of naturally produced insulin. It binds to insulin receptors on muscle, fat, and liver cells, triggering a cascade that moves glucose transporters to the cell surface, enhances glucose uptake, and suppresses hepatic glucose production, thereby lowering blood sugar.

The dose of Insulatard Innolet is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, blood‑glucose targets, and response to therapy. Dosing adjustments are made during follow‑up visits to achieve optimal glycemic control.

Insulatard Innolet is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy or lactation if the potential benefits justify the potential risks, and only under medical supervision.

To order Insulatard Innolet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling), and required import documentation.

Insulatard Innolet contains human insulin, which has a slower onset and longer duration compared with rapid‑acting insulin analogues. Compared with other basal insulins such as insulin glargine or detemir, it may have a slightly less predictable profile but remains an effective option for many patients, especially where cost considerations are important.

Insulatard Innolet must be stored in a refrigerator at 2‑8 °C. Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the solution can be kept at room temperature (up to 25 °C) for a limited period, typically 28 days, as indicated on the label.

Insulatard Innolet is administered by subcutaneous injection, usually into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce lipodystrophy. Patients are instructed by healthcare professionals on proper technique, needle length, and timing relative to meals and other medications.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from local skin reactions to anaphylaxis. Patients should be educated to recognize early signs of hypoglycemia and to seek immediate medical attention for any signs of a severe allergic response.

Insulatard Innolet should not be used by individuals with a known hypersensitivity to human insulin or any of the excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia until the condition is corrected, and in those with severe renal or hepatic failure without careful medical supervision.